8月26日晚间，哈尔滨三联药业股份有限公司（简称"哈三联"）交出了一份营收、净利润双降的半年度 成绩单。自去年起，哈三联业绩开始下滑，今年一季度更是陷入亏损状态。数据显示，2025年上半年， 哈三联实现营收约4.13亿元，同比减少21.08%；归属于上市公司股东的净利润亏损约9239万元，同比减 少451.68%。 作为哈三联的核心业务板块，医药板块上半年营收规模持续承压，成为公司业绩亏损的主要拖累。哈三 联披露，报告期内，受集采联动降价及市场竞争加剧等因素影响，公司医药板块营收规模持续承压，实 现销售收入3.56亿元，同比下降24.25%，占营业收入的86.08%。 其中，输液产品实现销售收入1.32亿元，同比下降12.14%。非输液产品受益于集采中标，小容量注射 剂、固体制剂产品销量同比均实现了较快增长，但由于重点产品盐酸昂丹司琼注射液执行集采后价格下 降，降幅达56.85%，导致小容量注射剂营收同比下降37.91%，冻干粉针剂产品注射用炎琥宁因政策增 加黑框警示语，本期收入同比下降明显，降幅达86.07%。受制于整体销售收入的下降，本期制剂产品 毛利率同比下降15.65%。受制于整体销售收入下降及部分产 ...

8月26日晚间，哈尔滨三联药业股份有限公司（简称"哈三联"）交出了一份营收、净利润双降的半年度 成绩单。自去年起，哈三联业绩开始下滑，今年一季度更是陷入亏损状态。数据显示，2025年上半年， 哈三联实现营收约4.13亿元，同比减少21.08%；归属于上市公司股东的净利润亏损约9239万元，同比减 少451.68%。 核心业务板块营收大幅下滑 资料显示，哈三联始建于1996年，2017年9月22日在深圳证券交易所成功上市，是一家面向国内外、具 有多品种、多剂型的医药上市公司，主要从事医药、动物保健和大健康领域相关产品的研发、生产和销 售。 作为哈三联的核心业务板块，医药板块上半年营收规模持续承压，成为公司业绩亏损的主要拖累。哈三 联披露，报告期内，受集采联动降价及市场竞争加剧等因素影响，公司医药板块营收规模持续承压，实 现销售收入3.56亿元，同比下降24.25%，占营业收入的86.08%。 其中，输液产品实现销售收入1.32亿元，同比下降12.14%。非输液产品受益于集采中标，小容量注射 剂、固体制剂产品销量同比均实现了较快增长，但由于重点产品盐酸昂丹司琼注射液执行集采后价格下 降，降幅达56.85%，导致小 ...

8月27日，辰欣药业跌5.07%，截至发稿，报26.80元/股，成交4.10亿元，换手率3.30%，总市值121.34亿 元。 资料显示，辰欣药业股份有限公司位于山东省济宁市高新区同济路16号，成立日期1998年11月6日，上 市日期2017年9月29日，公司主营业务涉及从事化学制剂药物的研究开发和生产经营业务。主营业务收 入构成为：小容量注射剂30.05%，大输液-塑瓶23.12%，大输液-非PVC软包15.02%，口服固体制剂 12.87%，大输液-玻瓶5.53%，冻干粉针剂4.17%，膏剂4.16%，滴剂3.36%，原料(自产外销)1.00%，冲洗 剂0.45%，其他(补充)0.25%。 从基金十大重仓股角度 数据显示，天弘基金旗下1只基金重仓辰欣药业。天弘优质成长企业精选混合发起式A（007202）二季 度持有股数17.04万股，占基金净值比例为2.41%，位居第九大重仓股。根据测算，今日浮亏损失约 24.37万元。 天弘优质成长企业精选混合发起式A（007202）成立日期2019年10月18日，最新规模9344.04万。今年以 来收益19.17%，同类排名3914/8194；近一年收益34.05%， ...

Core Points - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., has received a renewed Drug Production License from the Hainan Provincial Drug Administration, ensuring its continued operations [1][2][3] - The previous license was set to expire on November 5, 2025, and the new license is valid until August 7, 2030 [1] - The company specializes in the production of small-volume injectables, lyophilized powder injections, raw materials, and large-volume injectables [1] Company Information - Company Name: Hainan Shuangcheng Pharmaceutical Co., Ltd. [1] - Registered Address: No. 16, Xingguo Road, Xiuying District, Haikou City [1] - Legal Representative: Wang Chengdong [1] - Quality Responsible Person: Li Yuan [1] - License Number: Qiong 20150028 [1] - Daily Supervision Management Agency: Hainan Provincial Drug Administration [1] License Details - The new Drug Production License was issued due to the impending expiration of the previous license [1] - The renewal of the license is expected to have no significant impact on the company's production and operations [1]

Group 1 - The company announced a change of registered address for its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., due to operational development needs [1] - The new registered address is located at the Economic and Technological Development Zone in Wangcheng, Changsha City, Hunan Province [1] - The company has completed the relevant industrial and commercial registration procedures and obtained a new business license approved by the Wangcheng Economic and Technological Development Zone Management Committee [1] Group 2 - Hunan Sailong Pharmaceutical Co., Ltd. is a limited liability company with a registered capital of 28 million yuan [1] - The company was established on April 13, 2007, and its legal representative is Long Zhixiang [1] - The business scope includes the production and sales of various pharmaceutical products, including sterile raw materials and medical devices, as well as research and development activities [1]

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]

General Information - Chongqing Pharscin Pharmaceutical Co., Ltd. was established as a joint-stock company in accordance with the Company Law of the People's Republic of China [2] - The company was registered with the Chongqing Market Supervision Administration and obtained its business license on September 22, 2017, with a registered capital of RMB 417.596314 million [2][3] - The company issued 40.06 million shares to the public and was listed on the Shenzhen Stock Exchange on October 20, 2017 [2][3] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [3] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3] Management and Governance - Senior management includes the general manager, deputy general managers, financial officer, and board secretary [4] - The company has established a party organization in accordance with the Communist Party of China regulations, which plays a leading role in governance [4] Business Objectives and Scope - The company's business objective is to promote national medicine and provide quality healthcare products [4] - The business scope includes the production of various pharmaceutical forms, including injections, tablets, and traditional Chinese medicine, as well as related consulting and technology transfer services [4][5] Share Issuance and Capital Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued at the establishment was 300 million, with a par value of RMB 1 per share [6] - The company has a total of 417.596314 million shares issued, all of which are ordinary shares [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company governance [12] - Shareholders must comply with laws and the company's articles of association, and they are liable for their subscribed capital [40] - The company has provisions for shareholders to request the convening of a general meeting under certain conditions [52][57] Corporate Governance and Decision-Making - The general meeting of shareholders is the company's authority, responsible for electing directors and approving major corporate actions [46] - The company must hold an annual general meeting within six months after the end of the fiscal year [51] - Decisions regarding significant transactions and capital changes require shareholder approval [47][50] Financial Management and Investment - The company is required to disclose financial information and adhere to regulations regarding financial assistance and investments [21][49] - The company can engage in financial investments within approved limits and must disclose significant financial activities [48][49]

Core Insights - The company reported a revenue of 1.132 billion yuan in 2024, a decrease of 4.58% year-on-year, and a net profit attributable to shareholders of 58.68 million yuan, down 20.35% year-on-year [1][2] - The company's net profit excluding non-recurring items saw a significant increase of 73.85%, reaching 53.23 million yuan [1][2] - Basic earnings per share decreased to 0.19 yuan, down 20.83% from the previous year [2] Financial Performance - Revenue for 2024 was 1,132,476,522.09 yuan, compared to 1,186,786,001.40 yuan in 2023, reflecting a decline of 4.58% [2] - Net profit attributable to shareholders was 58,675,175.44 yuan, down from 73,663,110.90 yuan, a decrease of 20.35% [2] - The net profit after excluding non-recurring items was 53,233,408.45 yuan, a substantial increase from 30,619,980.53 yuan, marking a growth of 73.85% [2] - Operating cash flow was 30,687,788.46 yuan, down 14.02% from the previous year [2] - Total assets at the end of 2024 were 3.80 billion yuan, a 10.38% increase from 3.44 billion yuan in 2023 [2] Business Segments - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, accounting for 87.34% of total revenue, facing pressure from centralized procurement policies [3] - The veterinary medicine segment saw a dramatic increase in revenue to 75.20 million yuan, up 740.79%, driven by the launch of the Lingbao veterinary project and increased demand in the animal health market [3] - The functional food sector grew by 170%, and the cosmetics sector grew by 100%, emerging as new growth areas for the company [3] Research and Development - The company invested 1.22 billion yuan in R&D in 2024, representing 10.78% of total revenue, with a capitalization rate of 13.83% [3] - Ongoing projects include the development of new drugs such as Nimodipine tablets and Asenapine sublingual tablets, with three new patents granted, bringing the total to 137 patents focused on the nervous and cardiovascular systems [3]

辰欣药业股份有限公司 CISEN PHARMACEUTICAL CO., LTD. （济宁高新区同济科技工业园） 首次公开发行股票招股说明书 （申报稿） 保荐机构（主承销商） （山东省济南市经七路 86 号） 辰欣药业股份有限公司招股说明书（申报稿） 辰欣药业股份有限公司招股说明书（申报稿） 发行价，或者上市后 6 个月期末收盘价低于发行价，持有公司 股票的锁定期限自动延长 6 个月；如遇除权、除息事项，上述 发行价作相应调整。 4、乾鼎投资、昆吾九鼎、东阳昊润、龙邦贸易、智仕九鼎、 宝寿九鼎、兴贤九鼎、盛世九鼎、卓兴九鼎及赵白雪等 21 名自 然人股东承诺：自公司股票上市之日起十二个月内不转让或者 委托他人管理其本次发行前已持有的发行人股份，也不由发行 人回购其持有的股份。 5、本次发行前间接持有公司股份的董事、监事或高级管理 人员韩延振、郝留山、卢秀莲、刘霁、张祥林、李峰、樊月玲、 张斌承诺：自公司股票上市之日起三十六个月内，不转让或者 委托他人管理其本次发行前间接持有的公司股份，也不由发行 人回购其间接持有的股份。间接所持股票在锁定期满后两年内 减持的，减持价格不低于发行价；公司上市后 6 个月内如公司 ...